{
  "id": "map_1889",
  "title": "Aciclovir (ACV) versus\\NValaciclovir (VACV)",
  "specialty": "Neurolog√≠a",
  "tag": "üìã Gu√≠a Cl√≠nica",
  "node_count": 89,
  "root": {
    "text": "Aciclovir (ACV) versus\\NValaciclovir (VACV)",
    "children": [
      {
        "text": "## Aciclovir (ACV)",
        "children": [
          {
            "text": "- Definici√≥n y Descubrimiento: An√°logo guanosina (9-[(2-hidroxietoxi)metil]guanina). Primer antiviral espec√≠fico vs HSV/VZV. Premio Nobel (G. Elion)",
            "children": []
          },
          {
            "text": "- Farmacocin√©tica (PK)",
            "children": [
              {
                "text": "- Formulaciones: Oral, Intravenosa (IV), T√≥pica",
                "children": []
              },
              {
                "text": "- Biodisponibilidad Oral: Baja (15-30%)",
                "children": []
              },
              {
                "text": "- Distribuci√≥n: Amplia (LCR, ves√≠culas, secreciones vaginales). Cruza placenta, secreta leche materna",
                "children": []
              },
              {
                "text": "- Excreci√≥n: Renal (85% sin metabolizar)",
                "children": []
              },
              {
                "text": "- T√≥pica: Baja penetraci√≥n estrato c√≥rneo -> baja eficacia sist√©mica",
                "children": []
              },
              {
                "text": "- Intravenosa (IV): Para enf. graves / inmunocomprometidos",
                "children": []
              }
            ]
          },
          {
            "text": "- Mecanismo\\Nde Acci√≥n",
            "children": [
              {
                "text": "- General: Inhibidor potente/selectivo replicaci√≥n ADN herpesvirus",
                "children": []
              },
              {
                "text": "- Activaci√≥n Selectiva\\N(Fosforilaci√≥n):",
                "children": [
                  {
                    "text": "- ACV --(Timidina Quinasa VIRAL)--> ACV Monofosfato",
                    "children": []
                  },
                  {
                    "text": "- ACV Monofosfato --(Quinasas CELULARES)--> ACV Trifosfato",
                    "children": []
                  },
                  {
                    "text": "- Resultado: Acumulaci√≥n ACV Trifosfato en c√©lulas infectadas (40-100x > no infectadas)",
                    "children": []
                  }
                ]
              },
              {
                "text": "- Acci√≥n ACV Trifosfato:",
                "children": [
                  {
                    "text": "- Compite con dATP por ADN polimerasa VIRAL (mayor afinidad por viral)",
                    "children": []
                  },
                  {
                    "text": "- Inhibici√≥n irreversible ADN polimerasa viral",
                    "children": []
                  },
                  {
                    "text": "- Terminaci√≥n cadena ADN viral",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "- Indicaciones\\NAprobadas FDA",
            "children": [
              {
                "text": "- Infecciones Herpes Simple (HSV 1 y 2): Primarias, Recurrentes, Supresi√≥n",
                "children": []
              },
              {
                "text": "- Infecciones Varicela Zoster (VZV): Varicela, Herpes Zoster",
                "children": []
              },
              {
                "text": "- Infecciones HSV/VZV en Inmunocomprometidos (VIH)",
                "children": []
              }
            ]
          },
          {
            "text": "- Otros Usos\\NDermatol√≥gicos",
            "children": [
              {
                "text": "- Variantes HSV: Gingivoestomatitis, Herpes labial recurrente, Eczema herpeticum, Panadizo herp√©tico",
                "children": []
              },
              {
                "text": "- Profilaxis HSV (resurfacing facial)",
                "children": []
              },
              {
                "text": "- Eritema Multiforme recurrente (asociado HSV), Sd. Stevens-Johnson (asociado HSV)",
                "children": []
              },
              {
                "text": "- Par√°lisis de Bell (con corticoides)",
                "children": []
              },
              {
                "text": "- Leucoplaquia oral vellosa (VEB)",
                "children": []
              },
              {
                "text": "- Profilaxis Varicela (contactos)",
                "children": []
              }
            ]
          },
          {
            "text": "- Inicio Terapia",
            "children": [
              {
                "text": "- HSV mucocut√°neo: Lo antes posible",
                "children": []
              },
              {
                "text": "- Recurrencias HSV: Iniciar en pr√≥dromo",
                "children": []
              },
              {
                "text": "- Varicela: Iniciar < 24h",
                "children": []
              },
              {
                "text": "- Herpes Zoster (inmunocompetente): Iniciar < 3 d√≠as",
                "children": []
              }
            ]
          },
          {
            "text": "- Indicaciones ACV IV: Casos\\Ngraves/inmunocomprometidos",
            "children": [
              {
                "text": "- HSV diseminado/neonatal/encefalitis/refractario oral. Eczema herpeticum",
                "children": []
              },
              {
                "text": "- Varicela gestante con neumon√≠a",
                "children": []
              },
              {
                "text": "- H. Zoster oft√°lmico grave, H. Zoster inmunocomprometido",
                "children": []
              }
            ]
          },
          {
            "text": "- Indicaciones\\NACV T√≥pico",
            "children": [
              {
                "text": "- Ung√ºento 5%: Herpes genital inicial, Lesiones mucocut√°neas leves (inmunocomprometidos)",
                "children": []
              },
              {
                "text": "- Crema: Leve beneficio herpes labial recurrente (inmunocompetentes)",
                "children": []
              }
            ]
          },
          {
            "text": "- Eficacia Cl√≠nica",
            "children": [
              {
                "text": "- Profilaxis Herpes Labial (VO): Efectiva",
                "children": []
              },
              {
                "text": "- VIH (dosis altas): Modesto beneficio supervivencia",
                "children": []
              },
              {
                "text": "- H. Zoster / Varicela: Reduce s√≠ntomas agudos, previene diseminaci√≥n (inmunocomprometidos).\\NNO afecta latencia/recurrencia/Neuralgia Post-Herp√©tica (NPH)",
                "children": []
              },
              {
                "text": "- ACV T√≥pico: Efecto limitado (principalmente inmunocomprometidos)",
                "children": []
              }
            ]
          },
          {
            "text": "- Efectos Adversos (EA)",
            "children": [
              {
                "text": "- Nefrotoxicidad IV: Cristaluria, nefropat√≠a obstructiva, nefritis intersticial (5%). IRA (raro).\\NRiesgo: dosis altas, deshidrataci√≥n, infusi√≥n r√°pida",
                "children": []
              },
              {
                "text": "- Toxicidad SNC IV (1%): Letargia, confusi√≥n, temblor, alucinaciones, convulsiones, coma.\\NAsociado a niveles altos/enf SNC base",
                "children": []
              },
              {
                "text": "- Reacciones Infusi√≥n IV: Flebitis, inflamaci√≥n",
                "children": []
              },
              {
                "text": "- Otros (VO/IV): GI (n√°useas, v√≥mito, diarrea), Cefalea, Malestar.\\NRaros: Cut√°neos, Aumento transaminasas, Citopenias",
                "children": []
              },
              {
                "text": "- T√≥pico: Irritaci√≥n local",
                "children": []
              }
            ]
          },
          {
            "text": "- Precauciones",
            "children": [
              {
                "text": "- Ajuste Dosis Renal: Requerido si ClCr < 50 ml/min (VO/IV). Dar dosis post-hemodi√°lisis",
                "children": []
              }
            ]
          },
          {
            "text": "- Interacciones: Pocas (no metabolismo CYP450)",
            "children": []
          },
          {
            "text": "- Contraindicaciones: Hipersensibilidad",
            "children": []
          }
        ]
      },
      {
        "text": "## Valaciclovir (VACV)",
        "children": [
          {
            "text": "- Definici√≥n: Prof√°rmaco de ACV (√âster L-valina)",
            "children": []
          },
          {
            "text": "- Desarrollo: Para aumentar biodisponibilidad oral ACV",
            "children": []
          },
          {
            "text": "- Farmacocin√©tica (PK)",
            "children": [
              {
                "text": "- Absorci√≥n: Mejor que ACV (transportador activo intestinal)",
                "children": []
              },
              {
                "text": "- Conversi√≥n: R√°pida y casi completa a ACV (metabolismo 1er paso intestinal/hep√°tico)",
                "children": []
              },
              {
                "text": "- Biodisponibilidad ACV post-VACV: ~70% (3-5 veces > ACV oral)",
                "children": []
              },
              {
                "text": "- Ventaja PK: Permite menor frecuencia administraci√≥n",
                "children": []
              }
            ]
          },
          {
            "text": "- Mecanismo Acci√≥n / Espectro Actividad: Id√©nticos a ACV",
            "children": []
          },
          {
            "text": "- Indicaciones Aprobadas FDA: Similares a ACV oral (HSV primario/recurrente/supresi√≥n, Herpes Zoster, HSV/VZV en VIH)",
            "children": []
          },
          {
            "text": "- Otros Usos Dermatol√≥gicos: Similares a ACV (Eritema Multiforme R ACV, profilaxis resurfacing, etc.)",
            "children": []
          },
          {
            "text": "- Inicio Terapia: Similar a ACV (<72h HZV). Ver Tablas 2 y 3 del documento original",
            "children": []
          },
          {
            "text": "- Efectos Adversos (EA):\\NGeneralmente similares a ACV",
            "children": [
              {
                "text": "- TTP/HUS (P√∫rpura Tromb√≥tica Trombocitop√©nica / Sd Hemol√≠tico Ur√©mico):\\NReportado raro/fatal con DOSIS ALTAS en SIDA/trasplantados",
                "children": []
              },
              {
                "text": "- SDRIFE: Reportado",
                "children": []
              }
            ]
          },
          {
            "text": "- Interacciones: Cimetidina/Probenecid reducen tasa conversi√≥n (no magnitud)",
            "children": []
          }
        ]
      },
      {
        "text": "## Comparaci√≥n VACV vs ACV",
        "children": [
          {
            "text": "- Ventajas Generales VACV: Mejor biodisponibilidad oral, dosificaci√≥n m√°s conveniente (mejor cumplimiento)",
            "children": []
          },
          {
            "text": "- Herpes Labial: VACV 2g BID x 1d (epis√≥dico); VACV 500mg OD (supresi√≥n)",
            "children": []
          },
          {
            "text": "- Herpes Genital:",
            "children": [
              {
                "text": "- 1er Episodio: VACV 1g BID x 10d = eficacia ACV 5x/d√≠a",
                "children": []
              },
              {
                "text": "- Supresi√≥n: VACV 500mg OD (<9 ep/a√±o)",
                "children": []
              },
              {
                "text": "- Reducci√≥n Transmisi√≥n: VACV 500mg OD reduce transmisi√≥n a pareja (-50%). No demostrado con ACV OD",
                "children": []
              },
              {
                "text": "- Lesiones Abortivas: VACV aumenta probabilidad abortar lesi√≥n si tto precoz (<6h). No descrito con ACV",
                "children": []
              }
            ]
          },
          {
            "text": "- Costo-Efectividad: VACV 500mg OD ventajoso (EEUU)",
            "children": []
          },
          {
            "text": "- Uso en VIH+: VACV 500mg BID > eficaz supresi√≥n vs VACV 1g OD o ACV 400mg BID. VACV reduce carga viral VIH rectal/plasma (coinfectados VIH/HSV-2)",
            "children": []
          },
          {
            "text": "- Herpes Zoster:",
            "children": [
              {
                "text": "- Eficacia Similar: En s√≠ntomas agudos/curaci√≥n rash",
                "children": []
              },
              {
                "text": "- Ventaja VACV: Reduce significativamente incidencia y severidad Neuralgia Post-Herp√©tica (NPH).\\NDolor post-lesi√≥n m√°s corto (40d vs 60d). Beneficio global ~25% sobre ACV",
                "children": []
              }
            ]
          },
          {
            "text": "- Profilaxis HSV (Resurfacing): VACV efectivo",
            "children": []
          },
          {
            "text": "- Eritema Multiforme Recurrente: VACV opci√≥n si ACV falla",
            "children": []
          }
        ]
      }
    ]
  },
  "related_maps": [
    {
      "id": "map_1633",
      "title": "ACV: ESCALAS DE UTILIDAD CL√çNICA"
    },
    {
      "id": "map_1640",
      "title": "Aciclovir (ACV) versus Valaciclovir (VACV)"
    },
    {
      "id": "map_1682",
      "title": "ARISTOTLE (2011)\\NApixaban vs Warfarin in AF\\N\\nApixaban superior a warfarina en FA:\\nReduce ACV 21%, sangrado mayor 31%, mortalidad 11%\\nMejor perfil general vs warfarina"
    },
    {
      "id": "map_1707",
      "title": "SHEP (1991)\\NSystolic Hypertension in\\nthe Elderly Program\\N\\n‚≠ê Tratar HTA sist√≥lica aislada\\Nen mayores de 60 a√±os\\NREDUCE ACV 36%"
    },
    {
      "id": "map_1712",
      "title": "BAFTA (2007)\\NBirmingham Atrial Fibrillation\\NTreatment of the Aged\\N\\n‚≠ê Warfarina SUPERIOR a aspirina\\Nen prevenci√≥n ACV en FA\\Nmayores de 75 a√±os"
    }
  ],
  "source_file": "08. Aciclovir (ACV) versus Valaciclovir (VACV)-2025.smmx",
  "created": "2026-02-07T15:43:04.472813"
}